BioMarin’s Bienaimé To Retire With Sales And Earnings Growth On Track
Genentech CEO Alexander Hardy will succeed Jean-Jacques Bienaimé, who has led the rare disease specialist for 18 years. Gene therapy Roctavian has gotten off to a slow commercial start.
You may also be interested in...
The company presented its pipeline to investors during an R&D day, outlining expansion plans for Voxzogo and Roctavian as well as several early pipeline drugs.
BioMarin has finally brought its hemophilia A gene therapy Roctavian market and is determined prove naysayers wrong, but must work with its limitations and a confusing US label.
New York has its eye on becoming a premier biotech hub and is investing heavily in life sciences. Experts weighed in on the positives and drawbacks of the city for biotechs at a new innovation campus called Cure.